Distinguishing benign from malignant adrenal masses by Francis, Isaac R
Cancer Imaging (2003) 3, 102–110
DOI: 10.1102/1470-7330.2003.0006 CI
REVIEW
Distinguishing benign from malignant adrenal masses
Isaac R Francis
Professor of Radiology, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan,
USA
Corresponding address: Isaac R Francis, Professor of Radiology, Department of Radiology, Box 30, University of
Michigan Health System, 1500, East Medical Center Drive, Ann Arbor, Michigan 48109-0030, USA.
E-mail: ifrancis@umich.edu
Date accepted for publication 5 November 2002
Abstract
The approach to the radiological and clinical evaluation of adrenal masses in the oncologic and non-oncologic patient
is discussed. In addition, the value of unenhanced and enhanced CT densitometry with emphasis on the washout
features to distinguish between lipid-rich and lipid-poor adenomas and malignant lesions is detailed. The roles of
magnetic resonance imaging and positron emission tomography in distinguishing benign from malignant adrenal
masses will also be discussed.
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Silent or incidental adrenal tumors
When evaluating the ‘silent’ or ‘incidental’ adrenal mass,
some clinical information is helpful in narrowing down
the differential considerations:
• a known underlying malignancy
• clinically overt or biochemical evidence for adrenal
dysfunction.
Non-oncological patient
In patients with no known malignancy, the most
important differentiation is between an adrenal carcinoma
and an incidental non-functioning adrenal adenoma. Most
adrenal cancers do ‘function’, and can be diagnosed by
elevated biochemical markers and therefore distinguished
from incidental adenomas.
Most surgeons will surgically remove all masses
larger than 5 cm in size, irrespective of their imaging
appearances (except for classical adrenal cysts and
adrenal myelolipomas), as the incidence of adrenal
carcinoma tends to be higher in masses of this size.
Masses ranging in size between 3 and 5 cm are in the
‘grey zone’. They require additional imaging such as
unenhanced/chemical-shift MRI to determine whether
or not the lesion is a lipid-rich adenoma, in addition
to biochemical evaluation to exclude a functioning
lesion/mass. Smaller lesions (1–3 cm) with a non-specific
appearance are usually presumed, in the absence of
adrenal dysfunction, to represent adenomas, although a
confirmatory imaging exam will usually be used to prove
their benign nature.
Metastatic disease to the adrenal glands without the
detection of a primary neoplasm is very rare.
Oncological patient
In oncological patients, differentiation between adenoma
and metastases is important, as it affects treatment strat-
egy. The tools available for making this distinction are:
• unenhanced CT
• enhanced CT and washout calculations
• chemical-shift MRI
• PET imaging
• adrenal biopsy.
This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI
provided to locate the paper.
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Figure 1 (a) Unenhanced images show a right adrenal mass (arrow) with a density measurement of 9 HU.
This is typical for a lipid-rich adenoma. (b) Unenhanced images show a left adrenal mass (arrow) which
measures 28 HU. This was a proven metastasis on subsequent biopsy.
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Figure 2 (a) Unenhanced images show a right adrenal mass (arrow) which measures 9 HU. (b) This has an
HU of 45 on the enhanced and (c) 20 on the delayed image. By enhancement washout calculations this mass
hasa washout of 70%, which is diagnostic of an adenoma. Subsequent follow-up imaging showed stability of
the mass.
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Figure 3 (a) Unenhanced images show a left adrenal mass (arrow) which measures 36 HU. (b) This has an
HU of 109 on the enhanced and (c) 76 on the delayed image. By enhancement washout calculations this mass
has a washout of 45%, which is diagnostic of a non-adenoma. On subsequent surgical resection, this was a
pheochromocytoma.
Unenhanced CT
If an adrenal mass measures 0 HU (Hounsfield units) or
less on unenhanced CT, the likelihood of it being a benign
mass is almost 100%. In several recent studies, high
specificity (greater than 90%) for adenoma diagnosis was
achieved using a density cut-off of equal to or less than
10 HU on unenhanced CT (Fig. 1(a)) [1–3]. While density
measurements of greater than 10 HU can be seen in
metastases, they can also be seen in lesions which are not
lipid rich (Fig. 1(b)). This is because both lipid-poor and
complicated (hemorrhagic) adenomas can have density
measurements of greater than 10 HU on unenhanced CT.
Enhanced CT densitometry and
washout features of adenomas and
non-adenomas
More recently, two separate studies by Szolar and
Korobkin have shown that adrenal adenomas have unique
washout features, very different from those of non-
adenomas on contrast-enhanced CT. In both studies,
adenomas had high washout rates of contrast material,
beginning at about 5 min and reaching a maximum
of about 50–60% at 15 min, following the intravenous
administration of iodinated contrast medium (Fig. 2)
[4–9]
. In contrast, non-adenomas tended to retain contrast
material and have significantly less washout (15–25%)
at 15 min (Fig. 3). Specificities of more than 90% were
achieved for the separation of adenomas from malignant
lesions in these two studies, using a threshold washout
percentage of greater than 50% [7,8].
Washout features of lipid-poor adenomas
Although lipid-poor adenomas account for between 5
and 15% of all adenomas, they pose a diagnostic
problem, as they cannot be reliably distinguished from
metastases on both unenhanced and enhanced CT using
Distinguishing benign from malignant adrenal masses 105
Mean Attenuation Values of 
Adrenal Masses
0
10
20
30
40
50
60
70
80
90
Unenhanced Enhanced Delayed
Enhanced
Lipid-rich
Lipid-poor
Nonadenomas
-10
Percentage Enhancement Washout and 
Relative Percentage Enhancement 
Washout of Adrenal Adenomas
0
10
20
30
40
50
60
70
80
True Percentage
Washout
Relative
Percentage
Washout
Lipid-rich
Lipid-poor
Nonadenoma
(a)
(b)
Figure 4 (a) Mean density measurements of lipid-rich, lipid-poor adenomas and non-adenomas on
unenhanced, enhanced and delayed CT images showing that differentiation between lipid-poor adenomas
and non-adenomas is not possible. (b) Mean percentage and relative percentage washout of lipid-rich, lipid-
poor adenomas and non-adenomas on unenhanced, enhanced and delayed CT images showing that lipid-poor
adenomas can be distinguished from non-adenomas.
density measurements alone (Fig. 4(a)). We recently
investigated the washout features of adenomas and
malignant lesions, and found that both lipid-rich and
lipid-poor adenomas do indeed share similar washout
characteristics and can therefore be distinguished from
malignant lesions. In a study of 18 lipid-poor adenomas,
we found that the relative washout percentage of lipid-
poor adenomas was 74% (similar to that of lipid-
rich adenomas), compared with 19% for non-adenomas
(optimal threshold washout percentage value greater than
or equal to 60%) (Fig. 4(b)) [9,10]. Therefore even lipid-
poor adenomas can be distinguished from metastases
using washout calculations.
Magnetic resonance imaging
Chemical-shift MRI is now the most commonly used
imaging technique to distinguish between adenomas and
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Figure 5 On the out-of-phase images, bilateral adrenal masses show pronounced loss of SI when compared
to the in-phase images using the spleen as a reference, proving that the masses contain lipid and are lipid-rich
adenomas.
ADRENAL CORTICAL CARCINOMA 
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Figure 6 A large right adrenal mass shows no loss of SI on the out-of-phase images when compared to in-
phase images using the spleen as a reference. This shows that the lesion is not a typical lipid-rich adenoma. This
was proved to be an adrenal cortical carcinoma on subsequent surgical resection.
metastases. The premise with this technique is that
most adenomas contain lipid and more than 80% are of
the lipid-rich variety [11]. In general, malignant adrenal
lesions do not contain lipid. In using lipid-sensitive
sequences, this technique is able to distinguish between
lipid-rich adenomas and most malignant lesions. For
accurate interpretation of these images, the in-phase and
out-of-phase images (where fat and water are in and
out-of-phase with each other) should be compared, and
the signal intensity (SI) of the adrenal mass should
be compared with that of a reference organ such as
the spleen. It is essential that the technical parameters
(except the echo time) be kept identical to ensure that
the observation is valid. Lipid-rich adenomas lose signal
on the chemical-shift or out-of-phase (opposed-phase)
images, while lipid-poor lesions will not lose signal. Thus
if a lesion loses SI, it is a lipid-rich adenoma (Fig. 5).
If it does not lose SI, all one can state is that the lesion
does not contain lipid and is therefore not a lipid-rich
adenoma. It may either be a malignant lesion or a lipid-
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Figure 7 Lipid-rich adenoma. (a) A low-density right adrenal mass (arrow) measuring 10 HU on unenhanced
CT. (b) Loss of SI on the out-of-phase MR image. (c) Abundant lipid is seen on histology.
poor adenoma (Fig. 6). These patients therefore need
further evaluation [11,12].
Comparison of unenhanced CT densitometry
and chemical-shift MRI
In two studies, these two techniques were used to evaluate
the same group of patients with adrenal adenomas. It
was shown that there was linear correlation between
unenhanced CT numbers of the adrenal masses, and
relative loss of SI on chemical-shift MRI [13,14]. This
suggests that both techniques evaluate the same tissue
composition of the adenoma, i.e. its lipid component.
In instances where unenhanced CT numbers were
indeterminate, chemical-shift MRI was not helpful and
vice versa. So whilst one of the two tests could be used
to determine whether or not an adrenal mass is a lipid-
rich adenoma, the two tests used in conjunction are not
complementary.
Histological correlation of unenhanced CT
densitometry and chemical-shift changes on
MR in adrenal adenomas
A study by Korobkin and colleagues correlated and
graded the low density of adrenal masses on unenhanced
CT and loss of SI on chemical-shift MR with the amount
of lipid in pathologically resected adenomas. In this study
it was convincingly shown that the degree of low density
seen on unenhanced CT and the loss of SI on the opposed
or out-of-phase MR images were directly related to the
amount of lipid seen histologically within these tumors
(Figs 7 and 8) [15].
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Figure 8 Lipid-poor adenoma. (a) A left adrenal mass (arrow) measuring 20 HU on unenhanced CT. (b) A
right adrenal mass (arrow) showing no loss of SI on the out-of-phase image. (c) Dense compact cells with no
lipid are seen on histology.
University of Michigan adrenal mass
characterisation protocol using CT
If an adrenal mass is seen on a contrast-enhanced staging
CT, we bring the patient back for a dedicated adrenal
CT. We initially perform unenhanced scans using 3–
5 mm thick slices through the adrenal mass. Then an
ROI (region of interest) is placed over the mass and if
the mass measures less than 10 HU, the workup stops,
as we have a diagnosis of a lipid-rich adenoma. If the
lesion measures greater than 10 HU, then we administer
100–120 ml of non-ionic IV contrast (3 ml=s) and then
re-scan the adrenal mass initially after a 60 s scan delay
followed by images at 15 min. Care must be taken
to use an imaging technique identical to that used for
the unenhanced scans. Identical-sized ROIs are used to
measure the density of the adrenal mass at the same
location on the unenhanced, early-enhanced and delayed-
enhanced images.
% enhancement washout
= density on enhanced CT− density on delayed CT
density on enhanced CT− density on unenhanced CT :
The optimal threshold value for a percentage enhance-
ment washout of greater than or equal to 60% has a
specificity of 95% and sensitivity of 79–89% for adenoma
diagnosis.
If the unenhanced scan’s data are not available, then
the relative percentage enhancement washout can be
calculated as:
relative % enhancement washout
= density on enhanced CT− density on delayed CT
density on enhanced CT
:
For the diagnosis of an adenoma using relative percentage
enhancement washout, the optimal threshold value is a
value equal to 50% or greater than 50% [6–10].
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Figure 9 In a patient with colon cancer and rising CEA (carcino-embryonic antigen). (a) CT shows right
adrenal mass (arrow), (b) which takes up FDG on PET scan. Biopsy confirmed metastatic disease.
(a) (b)
Figure 10 (a) In a patient with lung cancer, CT shows a left adrenal mass, (b) which demonstrates no FDG
uptake. Follow-up imaging confirmed stability, suggesting that it is an adenoma.
PET–FDG imaging
Initial studies have suggested very high accuracy and
specificity for distinguishing adenoma from metastases,
although infrequently benign lesions can show increased
FDG uptake. Metastases in general have high FDG
uptake (Fig. 9) while most adenomas are not FDG avid
(Fig. 10) [16,17]. PET–FDG imaging is being used with
increasing frequency in whole-body staging of various
malignancies and will emerge as an excellent tool in
the differentiation between benign and malignant adrenal
lesions.
Adrenal biopsy
Although adrenal biopsy is a very valuable tool in the
differentiation between metastases and adrenal adenoma,
it is less frequently used than in days prior to the
use of unenhanced CT densitometry and chemical-shift
MRI. CT and MR are now being used to triage which
patients will require biopsy or operation. So at our
institution, adrenal biopsies are performed only when
imaging studies are equivocal and a malignant lesion is
strongly suspected.
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